We have identified an antibiotic drug lead, named MGC-10, which kills Gram positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), with a MIC (minimum inhibitory concentration) of 6 μM, while being harmless to mammalian cells in vitro in that concentration range. The antibacterial activity of MGC-10 was broad against over 50 strains of antibiotic-resistant samples obtained from hospital infections, where MGC-10 inhibited all tested strains of MRSA . The target for the MGC-10 activity is the ternary complex comprised of elongation factor Tu (EF-Tu), an aminoacylated tRNA (aa-tRNA), and guanosine triphosphate (GTP). Ternary complex delivers amino acids to the growing protein chain, bringing aa-tRNA into the codon-programmed A-site of the ribosome. MGC-10 appears to have potential as a topical treatment for difficult-to-treat wounds or skin infections by gram-positive pathogens such as MRSA. In a mouse skin-infection model with MRSA, MGC-10 performed as well or better than the present topical drug of choice, mupirocin. The drug showed little if any accumulation in the livers of topically treated mice.
Building similarity graph...
Analyzing shared references across papers
Loading...
Wlodek Mandecki
Emanuel Goldman
Invention Disclosure
Rutgers, The State University of New Jersey
Building similarity graph...
Analyzing shared references across papers
Loading...
Mandecki et al. (Sat,) studied this question.
www.synapsesocial.com/papers/69a76128c6e9836116a2ed2b — DOI: https://doi.org/10.1016/j.inv.2026.100048